Management of hepatitis C in HIV and/or HBV co-infected patients

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 517-530

  Fernández Montero, José Vicente ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Cirrhosis; Co infection; Direct acting antivirals; Hepatitis B; Hepatitis C; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; BILIRUBIN; BOCEPREVIR; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; HLA B57 ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; PROTHROMBIN; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLASSIFICATION ALGORITHM; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG INDICATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; ECHOGRAPHY; END STAGE LIVER DISEASE; EPIDEMIOLOGICAL DATA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MIXED INFECTION; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYPHARMACY; PRURITUS; RASH; RISK FACTOR; SCREENING; SERODIAGNOSIS; SUPERINFECTION; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COINFECTION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PROSPECTIVE STUDIES;

EID: 84870467175     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.007     Document Type: Article

References (94)

1. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
2. P. Tuma, J. Medrano, S. Resino, E. Vispo, A. Madejón, and C. Sánchez-Piedra Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of the highly active antiretroviral therapy Antivir Ther 15 2010 881 886
3. M. Hernandez, and K. Sherman HIV/hepatitis C coinfection natural history and disease progression Curr Opin HIV AIDS 6 2011 478 482
4. P. Tuma, I. Jarrin, J. Del Amo, E. Vispo, J. Medrano, and L. Martín-Carbonero Survival of HIV-infected patients with compensated liver cirrhosis AIDS 24 2010 745 753
5. V. Soriano, E. Vispo, and P. Labarga Viral hepatitis and HIV co-infection Antivir Res 85 2010 303 315
6. Soriano V. A new era for hepatitis C - new diagnostic tools and new weapons. ACS Med Chem Lett, in press.
7. V. Soriano, E. Vispo, and P. Barreiro New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B AIDS 25 2011 1013 1014
8. I. Jimenez-Nacher, E. Alvarez, J. Morello, S. Rodriguez-Novoa, S. de Andres, and V. Soriano Approaches for understanding and predicting drug interactions in HIV-infected patients Expert Opin Drug Metab Toxicol 7 2011 457 477
9. T. van de Laar, G. Matthews, M. Prins, and M. Danta Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection AIDS 24 2010 1799 1812
10. CDC Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York City, 2005-2010 MMWR 60 2011 945 950
11. D.L. Thomas, J. Astemborski, R.M. Rai, F.A. Anania, M. Schaeffer, and N. Galai The natural history of hepatitis C virus infection: host, viral and environmental factors JAMA 284 2000 450 456
12. J. Dionne-Odom, M. Osborn, H. Radziewicz, A. Grakoui, and K. Workowski Acute hepatitis C and HIV coinfection Lancet Infect Dis 9 2009 775 783
13. D. Netski, T. Mosbruger, E. Depla, G. Maertens, S.C. Ray, and R.G. Hamilton Humoral immune response in acute hepatitis C virus infection Clin Infect Dis 41 2005 667 675
14. NEAT Acute Hepatitis C Consensus Panel Acute hepatitis C in HIV-infected individuals: recommendations from the NEAT Consensus Conference AIDS 25 2012 399 409
15. M. Sulkowski Viral hepatitis and HIV coinfection J Hepatol 48 2008 353 367
16. F. Torriani, M. Rodriguez-Torres, J. Rockstroh, E. Lissen, J. Gonzalez-García, and A. Lazzarin Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
17. F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, and A. Benzekri Pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2004 2839 2848
18. M. Nuñez, C. Miralles, M.A. Berdun, E. Losada, K. Aguirrebengoa, and A. Ocampo Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial AIDS Res Hum Retroviruses 23 2007 972 982
19. P. Labarga, P. Barreiro, A. da Silva, J.M. Guardiola, R. Rubio, and K. Aguirrebengoa Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial J Infect Dis 206 6 2012 961 968
20. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis. Presented at: 19th conference on retroviruses and opportunistic infections; March 5-8, 2012; Seattle, WA. Abstract 46.
21. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HIV/HCV co-infected patients: end of treatment week 48 interim results. Presented at: 47th EASL, Barcelona, April 2012. Abstract 366.
22. V. Soriano, K. Sherman, J. Rockstroh, D. Dieterich, D. Back, and M. Sulkowski Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus coinfected patients AIDS 25 2011 2197 2208
23. C. Castellares, P. Barreiro, L. Martin-Carbonero, P. Labarga, M.E. Vispo, and R. Casado Liver cirrhosis in HIV-infected patients: prevalence, etiology and clinical outcome J Viral Hepat 15 2008 165 172
24. L. Martin-Carbonero, Y. Benhamou, M. Puoti, J. Berenguer, J. Mallolas, and C. Quereda Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European Collaborative Study Clin Infect Dis 38 2004 128 133
25. R. Weber, C. Sabin, N. Friis-Moller, P. Reiss, W.M. El-Sadr, and O. Kirk Liver-related deaths in persons infected with the HIV: the D: A:D study Arch Intern Med 166 2006 1632 1641
26. M. Sulkowski, and Y. Benhamou Therapeutic issues in HIV/HCV-coinfected patients J Viral Hepat 14 2007 371 386
27. P. Labarga, V. Soriano, M.E. Vispo, J. Pinilla, L. Martin-Carbonero, and C. Castellares epatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients J Infect Dis 196 2007 670 676
28. C. Wyatt, C. Malvestutto, S. Coca, P.E. Klotman, and C.R. Parikh The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis AIDS 22 2008 1799 1807
29. M. Alter, L. Seeff, B. Bacon, D.L. Thomas, M.O. Rigsby, and A.M. Di Bisceglie Testing for hepatitis C virus infection should be routine for persons at increased risk for infection Ann Intern Med 141 2004 715 717
30. V. Soriano, M. Puoti, M. Sulkowski, A. Cargnel, Y. Benhamou, and M. Peters Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel AIDS 21 2007 1073 1089
31. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
32. G.D. Kirk, J. Astemborski, S.H. Mehta, C. Spoler, C. Fisher, and D. Allen Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection Clin Infect Dis 48 2009 963 972
33. I. Maida, V. Soriano, P. Barreiro, P. Rivas, P. Labarga, and M. Núñez Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases AIDS Res Hum Retroviruses 23 2007 801 804
34. V. Soriano, and J. Garcia-Samaniego Liver biopsy in HIV-infected patients: pros and cons HIV Clin Trials 3 2002 351 353
35. L. Sandrin, B. Fourquet, J. Hasquenoph, S. Yon, C. Fournier, and F. Mal Transient elastography: a new noninvasive method for assessment of hepatic fibrosis Ultrasound Med Biol 29 2003 1705 1713
36. M. Ziol, A. Handra-Luca, A. Kettaneh, C. Christidis, F. Mal, and F. Kazemi Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C Hepatology 41 2005 48 54
37. J. Foucher, E. Chanteloup, J. Vergniol, L. Castéra, B. Le Bail, and X. Adhoute Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study Gut 55 2006 403 408
38. V. de Lédinghen, C. Douvin, A. Kettaneh, M. Ziol, D. Roulot, and P. Marcellin Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients J Acquir Immune Defic Syndr 41 2006 175 179
39. L. Castéra Transient elastography and other non-invasive test to assess hepatic fibrosis in patients with viral hepatitis J Viral Hepat 16 2009 300 314
40. J. Stebbing, L. Farouk, G. Panos, M. Anderson, L.R. Jiao, and S. Mandalia A meta-analysis of transient elastography for the detection of hepatic fibrosis J Clin Gastroenterol 44 2010 214 219
41. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
42. V. Soriano, I. Maida, M. Nuñez, J. García-Samaniego, P. Barreiro, and L. Martín-Carbonero Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies Antivir Ther 9 2004 987 992
43. E. Lissen, N. Clumeck, R. Sola, M. Mendes-Correa, J. Montaner, and M. Nelson Histological response to pegIFN alpha-2a (40 KD) plus ribavirin in HIV-hepatitis C virus co-infection AIDS 20 2006 2175 2181
44. V. Soriano, P. Labarga, A. Ruiz-Sancho, J. Garcia-Samaniego, and P. Barreiro Regression of liver fibrosis in HCV-HIV co-infected patients after treatment with pegylated interferon plus ribavirin AIDS 20 2006 2225 2227
45. J. Berenguer, J. Álvarez-Pellicer, and P. Miralles Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus Hepatology 50 2009 407 413
46. J. Berenguer, E. Rodríguez, P. Miralles, M.A. Von Wichmann, J. López-Aldeguer, and J. Mallolas Sustained virological response to interferon plus ribavirin reduces non-liverrelated mortality in patients coinfected with HIV and hepatitis C virus Clin Infect Dis 55 5 2012 728 736
47. P. Barreiro, E. Vispo, P. Labarga, and V. Soriano Management and treatment of chronic hepatitis C in HIV patients Semin Liver Dis 32 2012 138 146
48. M. Romero-Gomez, M. Viloria, R. Andrade, J. Salmerón, M. Diago, and C.M. Fernández-Rodríguez Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641
49. S. Worm, N. Friis-Moller, M. Bruyand, A. D'Arminio Monforte, M. Rickenbach, and P. Reiss High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome AIDS 24 2010 427 435
50. D. Sylvestre Treating hepatitis C in methadone maintenance patients: an interim analysis Drug Alcohol Depend 67 2002 117 123
51. J. Kiser, J. Burton, P. Anderson, and G.T. Everson Review and management of drug interactions with boceprevir and telaprevir Hepatology 55 2012 1620 1628
52. D. Ge, J. Fellay, A. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
53. N. Rallon, S. Naggie, J.M. Benito, J. Medrano, C. Restrepo, and D. Goldstein Association of a single nucleotide polymorphism near the interleukin 28B gene with response to hepatitis C therapy in HIV/HCV-coinfected patients AIDS 24 2010 F23 F29
54. T. Chu, R. Kulkarni, E. Gane, S.K. Roberts, C. Stedman, and P.W. Angus Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C Gastroenterology 142 2012 790 795
55. A. Fox, P. Vagefi, and P. Stock Liver transplantation in HIV patients Semin Liver Dis 32 2012 177 185
56. J. Medrano, K. Neukam, N. Rallon, A. Rivero, S. Resino, and S. Naggie Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV Clin Infect Dis 51 2010 1029 1116
57. M. Nuñez, N. Camino, B. Ramos, M.A. Berdún, P. Barreiro, and E. Losada Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 10 2005 657 662
58. A.L. Rendon, M. Nuñez, M. Romero, P. Barreiro, L. Martín-Carbonero, and J. García-Samaniego Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients J Acquir Immune Defic Syndr 39 2005 401 405
59. J.F. Jen, P. Glue, S. Gupta, D. Zambas, and G. Hajian Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 22 2000 555 565
60. F. Poordad, J. McCone, B. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
61. I. Jacobson, J. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
62. Pearlman B. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis, in press.
63. V. Soriano, E. Vispo, E. Poveda, P. Labarga, and P. Barreiro Treatment failure with new hepatitis C drugs Expert Opin Pharmacother 13 2012 313 323
64. K. Sherman, S. Flamm, N. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 65 2011 1014 1024
65. P. Kwo, E. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 HCV (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
66. C. Hezode, C. Dorival, F. Zoulim, T. Poynard, P. Mathurin, and S. Pol Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin in cirrhotic non-responders. First results of the French National Early Access Program: (ANRS CO20-CUPIC) J Hepatol 56 Suppl. 2 2012 Abstract 8
67. European AIDS Clinical Society HIV guidelines October 2011 www.europeanaidsclinicalsociety.org/guid2/
68. E. Poveda, E. Vispo, P. Barreiro, C. de Mendoza, P. Labarga, and J.V. Fernández-Montero Predicted effect of direct acting antivirals in the current HIV-HCV coinfected population in Spain Antivir Ther 17 2012 571 575
69. S. Naggie, and M. Sulkowski Management of patients coinfected with HCV and HIV: a close look at the role for direct acting antivirals Gastroenterology 142 2012 1324 1334
70. S. Zeuzem, M. Buti, P. Ferenci, J. Sperl, Y. Horsmans, and J. Cianciara Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia J Hepatol 44 2006 97 103
71. N. Shire, J. Welge, and K. Sherman Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis J Viral Hepat 14 2007 239 248
72. F. Torriani, R. Ribeiro, T. Gilbert, U.M. Schrenk, M. Clauson, and D.M. Pacheco HCV and HIV dynamics during HCV treatment in HCV/HIV co-infection J Infect Dis 188 2003 1498 1507
73. V. Soriano, M. Pérez-Olmeda, P. Ríos, M. Núñez, J. García-Samaniego, and J. González-Lahoz HCV relapses after anti-HCV therapy are more frequent in HIV-infected patients AIDS Res Hum Retroviruses 20 4 2004 351 353
74. A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren, and G. Palù Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients J Hepatol 42 2005 615 624
75. M. Buti, A. Valdes, F. Sanchez-Avila, R. Esteban, and Y. Lurie Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases Hepatology 37 2003 1226 1227
76. T. Berg, M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, and T. Gerlach Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon alfa-2a plus ribavirin Gastroenterology 130 2006 1086 1097
77. R. Myers, Y. Benhamou, M. Bochet, V. Thibault, D. Mehri, and T. Poynard Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy AIDS 18 2004 75 79
78. P. Labarga, E. Vispo, P. Barreiro, S. Rodríguez-Novoa, J. Pinilla, and J. Morello Rate and predictors of success in the re-treatment of chronic hepatitis C virus in HIV/HCV coinfected patients with prior non-response or relapse J Acquir Immune Defic Syndr 53 2010 364 368
79. M. Shiffman, A. di Bisceglie, K. Lindsay, C. Morishima, E.C. Wright, and G.T. Everson Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023
80. S. Crockett, and E. Keeffe Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection Ann Clin Microbiol Antimicrob 13 4 2005 13
81. C. Chu, and S. Lee Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment J Gastroenterol Hepatol 23 2008 512 520
82. A. Zignego, R. Fontana, S. Puliti, S. Barbagli, M. Monti, and G. Careccia Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis J Med Virol 51 1997 313 318
83. J. Crespo, J.L. Lozano, F. de la Cruz, L. Rodrigo, M. Rodríguez, and G. San Miguel Prevalence and significance of hepatitis C viremia in chronic active hepatitis B Am J Gastroenterol 89 1994 1147 1151
84. P. Bellecave, J. Gouttenoire, M. Gajer, E. Yip, B. Dewar, and S.A. Locarnini Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference Hepatology 50 2009 46 55
85. N. Eyre, R. Philips, S. Bowden, R.D. Aach, C.E. Stevens, and M. Cunningham Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells J Hepatol 51 2009 446 457
86. L. Mimms, J. Mosley, F. Hollinger, R.D. Aach, C.E. Stevens, and M. Cunningham Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection Br Med J 307 1993 1095 1097
87. Y. Liaw, Y. Chen, I. Sheen, R.N. Chien, C.T. Yeh, and C.M. Chu Impact of acute hepatitis C virus super-infection in patients with chronic hepatitis B virus infection Gastroenterology 126 2004 1024 1029
88. C. Chu The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B Gastroenterology 107 1994 189 195
89. Y. Liaw Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection J Gastroenterol 37 Suppl. 13 2002 65 68
90. Y. Liaw, C. Yeh, and S. Tsai Impact of acute hepatitis B virus super-infection on chronic hepatitis C virus infection Am J Gastroenterol 95 2000 2978 2980
91. L. Nguyen, S. Ko, S. Wong, P.S. Tran, H.N. Trinh, and R.T. Garcia Ethnic differences in viral dominance patterns in patients with HBV and HCV dual infection Hepatology 53 2011 1839 1845
92. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
93. C. Liu, W. Chuang, C. Lee, M.L. Yu, S.N. Lu, and S.S. Wu Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses Gastroenterology 136 2009 496 504
94. V. Soriano, P. Barreiro, L. Martin-Carbonero, C. Castellares, A. Ruiz-Sancho, and P. Labarga Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis J Infect Dis 195 2007 1181 1183